385 related articles for article (PubMed ID: 25111714)
1. No gain, no pain: NaV1.7 as an analgesic target.
King GF; Vetter I
ACS Chem Neurosci; 2014 Sep; 5(9):749-51. PubMed ID: 25111714
[TBL] [Abstract][Full Text] [Related]
2. Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na
Mulcahy JV; Pajouhesh H; Beckley JT; Delwig A; Du Bois J; Hunter JC
J Med Chem; 2019 Oct; 62(19):8695-8710. PubMed ID: 31012583
[TBL] [Abstract][Full Text] [Related]
3. Na
Vetter I; Deuis JR; Mueller A; Israel MR; Starobova H; Zhang A; Rash LD; Mobli M
Pharmacol Ther; 2017 Apr; 172():73-100. PubMed ID: 27916648
[No Abstract] [Full Text] [Related]
4. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief.
Emery EC; Luiz AP; Wood JN
Expert Opin Ther Targets; 2016 Aug; 20(8):975-83. PubMed ID: 26941184
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target Na
Rupasinghe DB; Herzig V; Vetter I; Dekan Z; Gilchrist J; Bosmans F; Alewood PF; Lewis RJ; King GF
Biochem Pharmacol; 2020 Nov; 181():114080. PubMed ID: 32511987
[TBL] [Abstract][Full Text] [Related]
6. Future potential and status of selective sodium channel blockers for the treatment of pain.
Priest BT
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):682-92. PubMed ID: 19736626
[TBL] [Abstract][Full Text] [Related]
7. The AMPK Activator A769662 Blocks Voltage-Gated Sodium Channels: Discovery of a Novel Pharmacophore with Potential Utility for Analgesic Development.
Asiedu MN; Han C; Dib-Hajj SD; Waxman SG; Price TJ; Dussor G
PLoS One; 2017; 12(1):e0169882. PubMed ID: 28118359
[TBL] [Abstract][Full Text] [Related]
8. Insensitivity to Pain upon Adult-Onset Deletion of Nav1.7 or Its Blockade with Selective Inhibitors.
Shields SD; Deng L; Reese RM; Dourado M; Tao J; Foreman O; Chang JH; Hackos DH
J Neurosci; 2018 Nov; 38(47):10180-10201. PubMed ID: 30301756
[TBL] [Abstract][Full Text] [Related]
9. Na
Yang Y; Mis MA; Estacion M; Dib-Hajj SD; Waxman SG
Trends Pharmacol Sci; 2018 Mar; 39(3):258-275. PubMed ID: 29370938
[TBL] [Abstract][Full Text] [Related]
10. Three Peptide Modulators of the Human Voltage-Gated Sodium Channel 1.7, an Important Analgesic Target, from the Venom of an Australian Tarantula.
Chow CY; Cristofori-Armstrong B; Undheim EA; King GF; Rash LD
Toxins (Basel); 2015 Jun; 7(7):2494-513. PubMed ID: 26134258
[TBL] [Abstract][Full Text] [Related]
11. Modulation of peripheral Na(+) channels and neuronal firing by n-butyl-p-aminobenzoate.
Thériault O; Poulin H; Sculptoreanu A; de Groat WC; O'Leary ME; Chahine M
Eur J Pharmacol; 2014 Mar; 727():158-66. PubMed ID: 24486399
[TBL] [Abstract][Full Text] [Related]
12. Dynamic-clamp analysis of wild-type human Nav1.7 and erythromelalgia mutant channel L858H.
Vasylyev DV; Han C; Zhao P; Dib-Hajj S; Waxman SG
J Neurophysiol; 2014 Apr; 111(7):1429-43. PubMed ID: 24401712
[TBL] [Abstract][Full Text] [Related]
13. Na(V)1.7 pain control: a novel target.
Hayes SB; Wang MY
Neurosurgery; 2013 Dec; 73(6):N16. PubMed ID: 24257339
[No Abstract] [Full Text] [Related]
14. Evaluation of the Spider (
Gonçalves TC; Lesport P; Kuylle S; Stura E; Ciolek J; Mourier G; Servent D; Bourinet E; Benoit E; Gilles N
Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31443554
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNa
Neff RA; Flinspach M; Gibbs A; Shih AY; Minassian NA; Liu Y; Fellows R; Libiger O; Young S; Pennington MW; Hunter MJ; Wickenden AD
J Biol Chem; 2020 Jan; 295(5):1315-1327. PubMed ID: 31871053
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of Nav1.7 functional expression in rat dorsal root ganglia neurons by using an electrical field stimulation assay.
Fouillet A; Watson JF; Piekarz AD; Huang X; Li B; Priest B; Nisenbaum E; Sher E; Ursu D
Mol Pain; 2017; 13():1744806917745179. PubMed ID: 29166836
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive properties of an isoform-selective inhibitor of Nav1.7 derived from saxitoxin in mouse models of pain.
Beckley JT; Pajouhesh H; Luu G; Klas S; Delwig A; Monteleone D; Zhou X; Giuvelis D; Meng ID; Yeomans DC; Hunter JC; Mulcahy JV
Pain; 2021 Apr; 162(4):1250-1261. PubMed ID: 33086288
[TBL] [Abstract][Full Text] [Related]
18. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models.
Xue Y; Chidiac C; Herault Y; Gaveriaux-Ruff C
Neurosci Lett; 2021 May; 753():135844. PubMed ID: 33775738
[TBL] [Abstract][Full Text] [Related]
19. Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs.
Thériault O; Poulin H; Beaulieu JM; Chahine M
Eur J Pharmacol; 2015 Oct; 764():395-403. PubMed ID: 26187311
[TBL] [Abstract][Full Text] [Related]
20. Allium macrostemon Bunge. exerts analgesic activity by inhibiting NaV1.7 channel.
Yang X; Dai Y; Ji Z; Zhang X; Fu W; Han C; Xu Y
J Ethnopharmacol; 2021 Dec; 281():114495. PubMed ID: 34364968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
